Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus-Reference-Cited by-同舟云学术

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus

Published:2017-04 Issue:4 Volume:16 Page:343-351
ISSN:1568-9972
Container-title:Autoimmunity Reviews
language:en
Short-container-title:Autoimmunity Reviews

Author:

Parodis Ioannis,Sjöwall Christopher,Jönsen Andreas,Ramsköld Daniel,Zickert Agneta,Frodlund Martina,Sohrabian Azita,Arnaud Laurent,Rönnelid Johan,Malmström Vivianne,Bengtsson Anders A.,Gunnarsson Iva

Funder

Swedish Research Council

Swedish Rheumatism Association

King Gustaf V′s 80-year Foundation

Swedish Society of Medicine

Professor Nanna Svartz Foundation

Swedish Heart–Lung Foundation

Foundation in memory of Clas Groschinsky

Stockholm and Östergötland County Councils

Karolinska Institutet Foundations

Lund University Medical Faculty Foundation

Alfred Österlund's Foundation

Anna-Greta Crafoord Foundation

Greta and Johan Kock's Foundation

Lund University Hospital

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference65 articles.

1. Survival study by organ disorders in 306 Japanese patients with systemic lupus erythematosus: results from a single center;Funauchi;Rheumatol Int,2007

2. Predictors of survival in systemic lupus erythematosus;Kasitanon;Medicine (Baltimore),2006

3. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus;Merrell;J Chronic Dis,1955

4. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10years;Chambers;Rheumatology (Oxford),2009

5. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value;Jacobsen;Clin Rheumatol,1998

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials;The Lancet Rheumatology;2024-08

2. Navigating the landscape of SLE treatment: An expert viewpoint on the rationality and limitations of early biologic intervention;Autoimmunity Reviews;2024-08

3. Advances in Systemic Lupus Erythematosus Treatment With Monoclonal Antibodies: A Mini-Review;Cureus;2024-07-08

4. Implementing a Staff‐Led Smoking Cessation Intervention in a Diverse Safety‐Net Rheumatology Clinic: A Pre‐Post Scalability Study in a Low‐Resource Setting;Arthritis Care & Research;2024-06-03

5. Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations;Annals of the Rheumatic Diseases;2024-05-22